Register
FDA approves blinatumomab for MRD-positive acute lymphoblastic leukemia |
Journal Updates
eMediNexus Coverage from: 
FDA approves blinatumomab for MRD-positive acute lymphoblastic leukemia
eMediNexus,  30 March 2018
remove_red_eye 692 Views
#Hematology #Nursing #Oncology #Pathology and Lab Medicine


comment                   
        



The US FDA has expanded the approval of blinatumomab (Blincyto) to include the treatment of B-cell precursor acute lymphoblastic leukemia (ALL), for patients in remission who still have minimal residual disease (MRD).


Comments

Comments on eMediNexus are moderated. We retain the right to remove any comments at our sole discretion.